To study the effectiveness and safety of artesunate + sulphadoxine- pyrimethamine in patients with uncomplicated falciparum malaria

Assessment of efficacy and safety of artesunate + sulfadoxine-pyrimethamine in patients with uncomplicated falciparum malaria.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/091/000047

Enrollment

Registered

2011-01-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- uncomplicated falciparum malaria

Interventions

Intervention1: Artesunate 100mg+Sulfadoxine 1500mg ? Tablet Pyrimethamine 75 mg: Control Intervention1: Nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 12 years 2. Slide confirmed cases with only plasmodium falciparum

Exclusion criteria

Exclusion criteria: 1. Presence of danger signs of Plasmodium falciparum (According to WHO Criteria) 2. Past history of hypersensitivity to sulfa drugs 3. History of recent uptake of malaria treatment.

Design outcomes

Primary

Measure	Time frame
Parasitological clearance on 28th dayTimepoint:	—

Secondary

Measure	Time frame
1). Fever clearance time (axillary temperature < 37.5oC) 2). Parasite Clearance time. Timepoint:	—

Countries

India

Contacts

Public ContactDr. Yash Goyal

dr_yashgoyal@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026